Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid

Miguel Martin, Richard Bell, Hugues Bourgeois, Adam Brufsky, Ingo Diel, Alexandru Eniu, Lesley Fallowfield, Yasuhiro Fujiwara, Jacek Jassem, Alexander H G Paterson, Diana Ritchie, Günther G. Steger, Alison T Stopeck, Charles Vogel, Michelle Fan, Qi Jiang, Karen Chung, Roger Dansey, Ada Braun

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Purpose: Denosumab was shown to be superior to zoledronic acid in preventing skeletal related events (SRE) in patients with breast cancer and bone metastases in a randomized, double-blind phase III study. We evaluated further results from this study related to skeletal complications and health-related quality of life (HRQoL). Experimental Design: Patients were randomized 1:1 to receive subcutaneous denosumab 120 mg (n = 1,026) and intravenous placebo, or intravenous zoledronic acid 4 mg (n = 1,020) and subcutaneous placebo every 4 weeks. Analyses reported here include the proportion of patients with one or multiple onstudy SREs, time to first radiation to bone, time to first SRE or hypercalcemia of malignancy, and change in HRQoL (functional assessment of cancer therapy-general). Results: Fewer patients receiving denosumab than zoledronic acid had an on-study SRE (31% vs. 36%, P = 0.006). The incidence of first radiation to bone was 12% (n = 123) with denosumab versus 16% (n = 162) with zoledronic acid. Denosumab prolonged the time to first radiation to bone by 26% versus zoledronic acid (HR, 0.74; 95% confidence interval [CI], 0.59-0.94, P = 0.012) and prolonged the time to first SRE or hypercalcemia of malignancy by 18% (HR, 0.82; 95% CI, 0.70-0.95; P = 0.007). Ten percent more patients had a clinically meaningful improvement in HRQoL with denosumab relative to zoledronic acid, regardless of baseline pain levels. Conclusions: Denosumab was superior to zoledronic acid in reducing bone-related complications of metastatic breast cancer and maintained HRQoL, providing an efficacious, well-tolerated treatment option for patients with bone metastases from breast cancer.

Original languageEnglish (US)
Pages (from-to)4841-4849
Number of pages9
JournalClinical Cancer Research
Volume18
Issue number17
DOIs
StatePublished - Sep 1 2012

Fingerprint

zoledronic acid
Quality of Life
Breast Neoplasms
Bone and Bones
Hypercalcemia
Radiation
Placebos
Confidence Intervals
Neoplasm Metastasis
Bone Neoplasms
Neoplasms
Denosumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bone-related complications and quality of life in advanced breast cancer : Results from a randomized phase III trial of denosumab versus zoledronic acid. / Martin, Miguel; Bell, Richard; Bourgeois, Hugues; Brufsky, Adam; Diel, Ingo; Eniu, Alexandru; Fallowfield, Lesley; Fujiwara, Yasuhiro; Jassem, Jacek; Paterson, Alexander H G; Ritchie, Diana; Steger, Günther G.; Stopeck, Alison T; Vogel, Charles; Fan, Michelle; Jiang, Qi; Chung, Karen; Dansey, Roger; Braun, Ada.

In: Clinical Cancer Research, Vol. 18, No. 17, 01.09.2012, p. 4841-4849.

Research output: Contribution to journalArticle

Martin, M, Bell, R, Bourgeois, H, Brufsky, A, Diel, I, Eniu, A, Fallowfield, L, Fujiwara, Y, Jassem, J, Paterson, AHG, Ritchie, D, Steger, GG, Stopeck, AT, Vogel, C, Fan, M, Jiang, Q, Chung, K, Dansey, R & Braun, A 2012, 'Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid', Clinical Cancer Research, vol. 18, no. 17, pp. 4841-4849. https://doi.org/10.1158/1078-0432.CCR-11-3310
Martin, Miguel ; Bell, Richard ; Bourgeois, Hugues ; Brufsky, Adam ; Diel, Ingo ; Eniu, Alexandru ; Fallowfield, Lesley ; Fujiwara, Yasuhiro ; Jassem, Jacek ; Paterson, Alexander H G ; Ritchie, Diana ; Steger, Günther G. ; Stopeck, Alison T ; Vogel, Charles ; Fan, Michelle ; Jiang, Qi ; Chung, Karen ; Dansey, Roger ; Braun, Ada. / Bone-related complications and quality of life in advanced breast cancer : Results from a randomized phase III trial of denosumab versus zoledronic acid. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 17. pp. 4841-4849.
@article{a437e6bbd6044f4ba0ec2e42d35ae48f,
title = "Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid",
abstract = "Purpose: Denosumab was shown to be superior to zoledronic acid in preventing skeletal related events (SRE) in patients with breast cancer and bone metastases in a randomized, double-blind phase III study. We evaluated further results from this study related to skeletal complications and health-related quality of life (HRQoL). Experimental Design: Patients were randomized 1:1 to receive subcutaneous denosumab 120 mg (n = 1,026) and intravenous placebo, or intravenous zoledronic acid 4 mg (n = 1,020) and subcutaneous placebo every 4 weeks. Analyses reported here include the proportion of patients with one or multiple onstudy SREs, time to first radiation to bone, time to first SRE or hypercalcemia of malignancy, and change in HRQoL (functional assessment of cancer therapy-general). Results: Fewer patients receiving denosumab than zoledronic acid had an on-study SRE (31{\%} vs. 36{\%}, P = 0.006). The incidence of first radiation to bone was 12{\%} (n = 123) with denosumab versus 16{\%} (n = 162) with zoledronic acid. Denosumab prolonged the time to first radiation to bone by 26{\%} versus zoledronic acid (HR, 0.74; 95{\%} confidence interval [CI], 0.59-0.94, P = 0.012) and prolonged the time to first SRE or hypercalcemia of malignancy by 18{\%} (HR, 0.82; 95{\%} CI, 0.70-0.95; P = 0.007). Ten percent more patients had a clinically meaningful improvement in HRQoL with denosumab relative to zoledronic acid, regardless of baseline pain levels. Conclusions: Denosumab was superior to zoledronic acid in reducing bone-related complications of metastatic breast cancer and maintained HRQoL, providing an efficacious, well-tolerated treatment option for patients with bone metastases from breast cancer.",
author = "Miguel Martin and Richard Bell and Hugues Bourgeois and Adam Brufsky and Ingo Diel and Alexandru Eniu and Lesley Fallowfield and Yasuhiro Fujiwara and Jacek Jassem and Paterson, {Alexander H G} and Diana Ritchie and Steger, {G{\"u}nther G.} and Stopeck, {Alison T} and Charles Vogel and Michelle Fan and Qi Jiang and Karen Chung and Roger Dansey and Ada Braun",
year = "2012",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-11-3310",
language = "English (US)",
volume = "18",
pages = "4841--4849",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Bone-related complications and quality of life in advanced breast cancer

T2 - Results from a randomized phase III trial of denosumab versus zoledronic acid

AU - Martin, Miguel

AU - Bell, Richard

AU - Bourgeois, Hugues

AU - Brufsky, Adam

AU - Diel, Ingo

AU - Eniu, Alexandru

AU - Fallowfield, Lesley

AU - Fujiwara, Yasuhiro

AU - Jassem, Jacek

AU - Paterson, Alexander H G

AU - Ritchie, Diana

AU - Steger, Günther G.

AU - Stopeck, Alison T

AU - Vogel, Charles

AU - Fan, Michelle

AU - Jiang, Qi

AU - Chung, Karen

AU - Dansey, Roger

AU - Braun, Ada

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Purpose: Denosumab was shown to be superior to zoledronic acid in preventing skeletal related events (SRE) in patients with breast cancer and bone metastases in a randomized, double-blind phase III study. We evaluated further results from this study related to skeletal complications and health-related quality of life (HRQoL). Experimental Design: Patients were randomized 1:1 to receive subcutaneous denosumab 120 mg (n = 1,026) and intravenous placebo, or intravenous zoledronic acid 4 mg (n = 1,020) and subcutaneous placebo every 4 weeks. Analyses reported here include the proportion of patients with one or multiple onstudy SREs, time to first radiation to bone, time to first SRE or hypercalcemia of malignancy, and change in HRQoL (functional assessment of cancer therapy-general). Results: Fewer patients receiving denosumab than zoledronic acid had an on-study SRE (31% vs. 36%, P = 0.006). The incidence of first radiation to bone was 12% (n = 123) with denosumab versus 16% (n = 162) with zoledronic acid. Denosumab prolonged the time to first radiation to bone by 26% versus zoledronic acid (HR, 0.74; 95% confidence interval [CI], 0.59-0.94, P = 0.012) and prolonged the time to first SRE or hypercalcemia of malignancy by 18% (HR, 0.82; 95% CI, 0.70-0.95; P = 0.007). Ten percent more patients had a clinically meaningful improvement in HRQoL with denosumab relative to zoledronic acid, regardless of baseline pain levels. Conclusions: Denosumab was superior to zoledronic acid in reducing bone-related complications of metastatic breast cancer and maintained HRQoL, providing an efficacious, well-tolerated treatment option for patients with bone metastases from breast cancer.

AB - Purpose: Denosumab was shown to be superior to zoledronic acid in preventing skeletal related events (SRE) in patients with breast cancer and bone metastases in a randomized, double-blind phase III study. We evaluated further results from this study related to skeletal complications and health-related quality of life (HRQoL). Experimental Design: Patients were randomized 1:1 to receive subcutaneous denosumab 120 mg (n = 1,026) and intravenous placebo, or intravenous zoledronic acid 4 mg (n = 1,020) and subcutaneous placebo every 4 weeks. Analyses reported here include the proportion of patients with one or multiple onstudy SREs, time to first radiation to bone, time to first SRE or hypercalcemia of malignancy, and change in HRQoL (functional assessment of cancer therapy-general). Results: Fewer patients receiving denosumab than zoledronic acid had an on-study SRE (31% vs. 36%, P = 0.006). The incidence of first radiation to bone was 12% (n = 123) with denosumab versus 16% (n = 162) with zoledronic acid. Denosumab prolonged the time to first radiation to bone by 26% versus zoledronic acid (HR, 0.74; 95% confidence interval [CI], 0.59-0.94, P = 0.012) and prolonged the time to first SRE or hypercalcemia of malignancy by 18% (HR, 0.82; 95% CI, 0.70-0.95; P = 0.007). Ten percent more patients had a clinically meaningful improvement in HRQoL with denosumab relative to zoledronic acid, regardless of baseline pain levels. Conclusions: Denosumab was superior to zoledronic acid in reducing bone-related complications of metastatic breast cancer and maintained HRQoL, providing an efficacious, well-tolerated treatment option for patients with bone metastases from breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84865753315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865753315&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-3310

DO - 10.1158/1078-0432.CCR-11-3310

M3 - Article

C2 - 22893628

AN - SCOPUS:84865753315

VL - 18

SP - 4841

EP - 4849

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -